Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABT-981, a human dual variable domain immunoglobulin simultaneously targeting interleukin (IL)-1α and IL-1β, in patients with knee osteoarthritis (OA). METHOD: This was a randomized, double-blind, placebo-controlled, single-center study of multiple subcutaneous (SC) injections of ABT-981 in patients with mild-to-moderate OA of the knee (NCT01668511). Three cohorts received ABT-981 (0.3, 1, or 3 mg/kg) or placebo every other week for a total of four SC injections, and one cohort received ABT-981 (3 mg/kg) or placebo every 4 weeks for a total of three SC injections. Assessment of safety and tolerability were the primary objectives. A panel of serum and urine biomarkers of inflammation and joint degradation were evaluated. RESULTS: A total of 36 patients were randomized (ABT-981, n = 28; placebo, n = 8); 31 (86%) completed the study. Adverse event (AE) rates were comparable between ABT-981 and placebo (54% vs 63%). The most common AE reported with ABT-981 vs placebo was injection site erythema (14% vs 0%). ABT-981 significantly reduced absolute neutrophil count and serum concentrations of IL-1α/IL-1β, high-sensitivity C-reactive protein, and matrix metalloproteinase (MMP)-derived type 1 collagen. Serum concentrations of MMP-derived type 3 collagen and MMP-degraded C-reactive protein demonstrated decreasing trends with ABT-981. Antidrug antibodies were found in 37% of patients but were not associated with the incidence or severity of AEs. CONCLUSION: ABT-981 was generally well tolerated in patients with knee OA and engaged relevant tissue targets, eliciting an anti-inflammatory response. Consequently, ABT-981 may provide clinical benefit to patients with inflammation-driven OA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778 · cited 2×
“All authors have made substantial contributions: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.”
BackgroundMethodUnderstanding the mechanism of IL-1β secretion
Lopez-Castejon, G., & Brough, D. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.10.001 · Cited by 1,519
Manz, M. G., & Boettcher, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3660 · Cited by 855
In Vivo Interleukin-6 Protects Neutrophils from Apoptosis in Osteomyelitis
Asensi, V., Valle, E., Meana, A., Fierer, J., Celada, A., Alvarez, V., Paz, J., Coto, E., Carton, J. A., Maradona, J. A., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.7.3823-3828.2004 · Cited by 93
Cited by
Osteoarthritis: pathogenic signaling pathways and therapeutic targets
Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., & Xiao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01330-w · Cited by 1,194
Therapeutic options for targeting inflammatory osteoarthritis pain
Conaghan, P. G., Cook, A. D., Hamilton, J. A., & Tak, P. P. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0221-y · Cited by 405
Interleukin-1β signaling in osteoarthritis – chondrocytes in focus
Jenei-Lanzl, Z., Meurer, A., & Zaucke, F. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2018.10.005 · Cited by 387
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Peng, Z., Sun, H., Bunpetch, V., Koh, Y., Wen, Y., Wu, D., & Ouyang, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120555 · Cited by 347
Yu, S. P., Deveza, L. A., Kraus, V. B., Karsdal, M., Bay-Jensen, A.-C., Collins, J. E., Guermazi, A., Roemer, F. W., Ladel, C., Bhagavath, V., et al. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03253-x · Cited by 7
Self-citation
Metadata
- Authors
- Wang, S. X., Abramson, S. B., Attur, M., Karsdal, M. A., Preston, R. A., Lozada, C. J., Kosloski, M. P., Hong, F., Jiang, P., Saltarelli, M. J., Hendrickson, B. A., & Medema, J. K.
- Venue
- Osteoarthritis and Cartilage
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 25
- Issue
- 12
- Pages
- 1952-1961
- ISSN
- 1063-4584 (ISSN-L)
- OpenAlex
- W2757127444
- Cited by
- 71
- References
- 4
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.